Jason Ryan - Foundation Medicine CFO
CFO
Mr. Jason Ryan serves as a Chief Financial Officer, Principal Financial Officer, Principal Accounting officer of the Company. Mr. Ryan has served as our Chief Financial Officer since March 2015, as our Senior Vice President, Finance from January 2014 to March 2015 and as our Vice President, Finance from March 2012 to January 2014. He previously served as our Senior Director, Finance from May 2011 to March 2012. Prior to joining us, Mr. Ryan led the finance and strategic planning functions of Taligen Therapeutics, Inc., which was acquired by Alexion Pharmaceuticals, Inc., from May 2009 to April 2011, Codon Devices Inc. from May 2007 to May 2009 and Genomics Collaborative, Inc., which was acquired by SeraCare Life Sciences, Inc., from September 1998 to September 2004. He began his career at Deloitte Touche since 2015.
| Age | 42 |
| Tenure | 9 years |
| Professional Marks | CPA |
| Phone | 617 418-2200 |
| Web | www.foundationmedicine.com |
Foundation Medicine Management Efficiency
Foundation Medicine's management efficiency ratios could be used to measure how well Foundation Medicine manages its routine affairs as well as how well it operates its assets and liabilities.The company has 90 M in debt with debt to equity (D/E) ratio of 476.2, demonstrating that the company may be unable to create cash to meet all of its financial commitments. Foundation Medicine has a current ratio of 2.22, demonstrating that it is liquid and is capable to disburse its financial commitments when the payables are due. Debt can assist Foundation Medicine until it has trouble settling it off, either with new capital or with free cash flow. So, Foundation Medicine's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Foundation Medicine sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Foundation to invest in growth at high rates of return. When we think about Foundation Medicine's use of debt, we should always consider it together with cash and equity.
Similar Executives
| Found 4 records | CFO Age | ||
| Timothy Deacon | Sun Life Financial | N/A | |
| Mark Castaneda | Primo Water Corp | 50 | |
| Shannon McLaren | Crimson Wine | 38 | |
| Jay Wells | Primo Water Corp | 61 | |
Management Performance
| Return On Equity | -2.0E-4 | |||
| Return On Asset | -1.0E-4 |
Foundation Medicine Leadership Team
Elected by the shareholders, the Foundation Medicine's board of directors comprises two types of representatives: Foundation Medicine inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Foundation. The board's role is to monitor Foundation Medicine's management team and ensure that shareholders' interests are well served. Foundation Medicine's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Foundation Medicine's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Daniel Day, Director | ||
| Michael Varney, Director | ||
| Krishna Yeshwant, Independent Director | ||
| David Daly, Chief Commercial Officer | ||
| David Schenkein, Independent Director | ||
| Melanie Nallicheri, Chief business Officer and head of Biopharma | ||
| Alexis Borisy, Chairman of the Board, Co-Founder | ||
| Steven Kafka, Pres and COO | ||
| Evan Jones, Independent Director | ||
| Vincent Miller, Chief Medical Officer | ||
| Konstantin Fiedler, COO | ||
| Michael Pellini, President CEO, Director | ||
| Robert Hesslein, Senior Vice President General Counsel | ||
| Sandra Horning, Director | ||
| Michael Doherty, Head of Product Development | ||
| Jason Ryan, CFO | ||
| Michael Dougherty, Director | ||
| Tom Civik, Chief Commercial Officer | ||
| Troy Cox, CEO, Director | ||
| Thomas Civik, Chief Commercial Officer |
Foundation Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Foundation Medicine a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -2.0E-4 | |||
| Return On Asset | -1.0E-4 | |||
| Profit Margin | (0.0001) % | |||
| Operating Margin | (83.98) % | |||
| Current Valuation | 5.09 B | |||
| Shares Outstanding | 37.14 M | |||
| Shares Owned By Insiders | 58.74 % | |||
| Shares Owned By Institutions | 36.24 % | |||
| Number Of Shares Shorted | 2.35 M | |||
| Price To Earning | (9.70) X |
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Foundation Medicine in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Foundation Medicine's short interest history, or implied volatility extrapolated from Foundation Medicine options trading.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Investing Opportunities to better understand how to build diversified portfolios. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in population. You can also try the Aroon Oscillator module to analyze current equity momentum using Aroon Oscillator and other momentum ratios.
Other Consideration for investing in Foundation Stock
If you are still planning to invest in Foundation Medicine check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Foundation Medicine's history and understand the potential risks before investing.
| AI Investment Finder Use AI to screen and filter profitable investment opportunities | |
| Positions Ratings Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Fundamental Analysis View fundamental data based on most recent published financial statements | |
| Analyst Advice Analyst recommendations and target price estimates broken down by several categories | |
| Earnings Calls Check upcoming earnings announcements updated hourly across public exchanges | |
| Pattern Recognition Use different Pattern Recognition models to time the market across multiple global exchanges | |
| Money Flow Index Determine momentum by analyzing Money Flow Index and other technical indicators | |
| Correlation Analysis Reduce portfolio risk simply by holding instruments which are not perfectly correlated |